Top Markets
#1 Islamic Coin Islamic Coin +152.63%
#2 Bitway Bitway +45.44%
#3 Starpower Starpower +37.89%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +37.74%
#5 Pons Pons +33.63%
#6 aelf aelf +26.00%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.55%
#8 SkyAI SkyAI +18.96%
#9 Ocean Protocol Ocean Protocol +16.67%
#10 Decred Decred +14.08%
Coin of the day
Islamic Coin Islamic Coin
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Aziyo Biologics, Inc. Aziyo Biologics, Inc.

Aziyo Biologics, Inc.

AZYO
Classificação em ações #29676
Aziyo Biologics, Inc. (AZYO) operates as a regenerative medicine firm,... Aziyo Biologics, Inc. (AZYO) operates as a regenerative medicine firm, concentrating its efforts on developing advanced medical products. Their primary applications target three key areas: implantable electronic devices and cardiovascular care, orthopedic and spinal repair, and the reconstruction of soft tissues. The company's product portfolio includes CanGaroo, an innovative envelope that incorporates antibiotics, specifically engineered to lower the risk of infection following the surgical implantation of an electronic device. Aziyo also provides a suite of cardiovascular solutions. ProxiCor serves as an intracardiac patch or pledget for repairing heart tissues, while Tyke is designed for neonates and infants to mend pericardial structures. Additionally, VasCure offers a versatile patching material for the repair or reconstruction of peripheral blood vessels, encompassing critical arteries like the carotid, renal, iliac, femoral, and tibial, serving cardiovascular, vascular, and general surgeons. For orthopedic procedures, Aziyo offers human tissue-derived bone allografts such as Fiber VBM, ViBone, and OsteGro V. These products are formulated to protect and preserve the body's natural bone cells. In the realm of soft tissue repair, they feature SimpliDerm, a pre-hydrated human acellular dermal matrix (HADM) developed for the repair or replacement of damaged or insufficient skin and related integumental tissues. Beyond its proprietary product line, Aziyo Biologics extends contract manufacturing services, producing various items for other corporate clients. The company distributes its products to hospitals and other healthcare facilities through a multi-faceted sales approach, utilizing its dedicated direct sales force, strategic commercial partners, and independent sales agents. Founded in 2015, Aziyo Biologics, Inc. maintains its headquarters in Silver Spring, Maryland.
Preço da ação
$1.39
Última sincronização: 2023-10-03
Valor de mercado
$20.11M
Variação (1 dia)
-3.47%
Variação (1 ano)
0.00%
País
US
Negociar Aziyo Biologics, Inc. (AZYO)

Categoria

Healthcare
Rácio P/E de Aziyo Biologics, Inc. (AZYO)
Rácio P/E em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Aziyo Biologics, Inc., o rácio P/E atual (TTM) é 0. No final de 2026, a empresa tinha um P/E de 0.
Histórico do rácio P/E da Aziyo Biologics, Inc. de 2026 a 2026
Rácio P/E no final de cada ano
Ano Índice P/E Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/E para empresas semelhantes ou concorrentes
Empresa Rácio P/E Diferença do rácio P/E País
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.64 -
US
Como interpretar um P/E Ratio?

O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.

Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.

Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.